How Dangerous Is the New COVID Variant? What We Know

Newer COVID variants, which are all descendants of Omicron, spread efficiently and dodge prior immunity better than their predecessors, but they generally cause less severe illness than the Delta or ancestral strains did, particularly in people with some combination of vaccination and prior infection. That reassuring headline comes with caveats: protection against getting infected at all fades within months, certain groups remain at serious risk, and the virus continues to evolve in ways that keep public health officials watching closely.

Why New Variants Keep Appearing

SARS-CoV-2 mutates as it replicates, and the mutations that help it spread faster or slip past existing immunity get selected for. The first two years of the pandemic saw key mutations popping up at the same handful of spots on the spike protein, independently across different lineages. Alpha, Beta, Gamma, and Delta all hit upon changes at positions like K417, L452, E484, N501, and P681. Since Omicron arrived, that convergent evolution has expanded to a broader set of positions, with different sublineages independently picking up mutations at sites like R346, K444, F486, and others.

¹

This convergent pattern means the virus keeps finding the same solutions to the same problem: how to bind to human cells while evading antibodies. The result is a constantly shifting landscape of subvariants rather than the dramatic single-variant takeovers we saw earlier in the pandemic. Researchers have described it as a “variant soup,” where many related lineages circulate at once and new waves emerge from whichever lineage accumulates the right combination of advantages first.

How Quickly New Variants Spread

One consistent trait across the pandemic’s variants of concern has been increasing transmissibility. When Delta arrived, it replaced previously dominant lineages in a matter of weeks in many countries and led to sharp spikes in infections and deaths.

² Omicron then outcompeted Delta with an even more dramatic growth advantage, estimated at roughly 64% across 40 countries, though the size of that advantage varied widely from place to place.³

Part of this transmissibility edge comes from the virus’s physical structure. Atomic-level studies of spike proteins across multiple variants have found an evolutionary trend: early variants became more flexible, then Delta shifted toward engaging multiple binding sites on each cell at once, and later Omicron sublineages moved toward stronger individual binding that compensates for using fewer attachment points.⁴ More recent Omicron subvariants like BA.5 and XBB.1.5 showed significantly higher binding affinity to human cells than the original Omicron BA.1 did, suggesting that within the Omicron family, the virus has continued optimizing how it latches on.⁵

But transmissibility is not the same as danger. A variant that infects more people is a public health concern even if each individual infection is milder, because the sheer volume of cases can still strain hospitals. That is what played out during early Omicron waves in many countries.

How New Variants Dodge Your Immune System

The other side of new variant dominance is immune evasion. Omicron and its descendants carry mutations both in and around the antibody-binding sites on the spike protein, which substantially reduce the ability of neutralizing antibodies to block infection.⁶ This affects antibodies generated by both natural infection and vaccination.

The numbers tell the story clearly. After two doses of the original mRNA vaccine, only about 28% of people had measurable neutralizing antibodies against Omicron two months later, and the antibody levels against Omicron were nearly 12-fold lower than those against the earlier D614G variant.⁷ This is why updated vaccines have been developed to better match circulating variants, and why public health agencies recommend keeping up with booster doses.

Are Newer Variants Less Severe?

On the whole, yes. A systematic review of studies comparing Omicron to earlier lineages found that patients infected with Omicron had significantly lower rates of hospitalization, ICU admission, need for mechanical ventilation, and death compared to those infected with Delta.⁸ A separate meta-analysis concluded that Omicron likely has genuinely lower intrinsic severity, possibly because it tends to infect the upper airways more than the deeper lung tissue, reducing the risk of pneumonia.⁹

That said, the picture has a wrinkle. One study from Hong Kong, which had a largely unvaccinated elderly population during its Omicron wave, found that Omicron’s intrinsic severity was comparable to the original Wuhan strain. The lower apparent severity seen elsewhere was largely explained by population-level immunity from vaccination.¹⁰ In other words, a big part of why Omicron “feels” milder is that most of us now have immune memory from prior infections, vaccines, or both. For someone with no prior immunity, the risk may not be as low as the population-level data suggests.

Symptoms and Incubation Time

The time between exposure and symptom onset has shifted somewhat with newer variants, though the evidence is not as clean-cut as you might expect. A small study comparing early Omicron BA.1 to Delta found a mean incubation period of about 3.5 days for Omicron versus 6.5 days for Delta.¹¹ However, a more rigorous analysis that corrected for growth-rate biases found that both Delta and Omicron had similar forward incubation periods of about four days.¹² A systematic review and meta-analysis found a trend toward shorter incubation periods with newer variants, but no statistically significant difference between variant groups.¹³

In practical terms, if you have been exposed, symptoms could appear anywhere from two to five days later. The symptom profile itself has shifted toward more upper-respiratory complaints: sore throat, runny nose, and fatigue are now more prominent than the loss of smell or taste that defined earlier waves.

How Well Do Updated Vaccines Work?

Updated vaccines still offer meaningful protection, especially against severe disease, though they are less effective at preventing infection altogether. The CDC reported that the 2023–2024 updated vaccine (targeting XBB.1.5) reduced symptomatic infection by about 54–58% in the first two months after vaccination, declining to roughly 49% by the two-to-four-month mark.¹⁴ Protection against infection wanes steadily, which is why updated boosters are offered annually.

Protection against hospitalization and severe disease holds up much better and lasts longer. A WHO meeting review found that vaccine effectiveness against severe Omicron disease was, on average, higher and more durable than effectiveness against infection, though some studies did observe waning over time.¹⁵ The best protection comes from “hybrid immunity,” the combination of vaccination and prior infection. A large systematic review found that hybrid immunity maintained about 97% effectiveness against hospitalization or severe disease at 12 months, even as protection against reinfection waned to around 42% over the same period.¹⁶

Do Antivirals Still Work Against New Variants?

Paxlovid (nirmatrelvir/ritonavir), the most widely prescribed oral antiviral, targets a viral enzyme called the main protease, which is much more conserved across variants than the spike protein. Laboratory studies have shown that nirmatrelvir remains effective against all tested variants of concern, including Omicron, because the known mutations in this enzyme do not involve the drug’s binding site.¹⁷ Real-world data from South Korea during the BA.5 wave confirmed this: among patients 60 and older, Paxlovid treatment cut the risk of severe illness or death by about 46%, regardless of vaccination status.¹⁸

This is genuinely good news. While vaccine-derived antibody protection against infection erodes as the virus mutates, antiviral drugs that target the virus’s internal machinery rather than its surface remain a reliable safety net for high-risk patients.

Long COVID With Newer Variants

The risk of developing long-lasting symptoms after infection appears to be lower with Omicron variants compared to earlier strains. One study comparing pre-Omicron and Omicron-era patients found that long COVID prevalence dropped from about 67% to 48%. Specific lingering symptoms like fatigue, shortness of breath, smell and taste loss, chest pain, and concentration difficulties all occurred at lower rates in the Omicron group.¹⁹ A broader review echoed this, noting that long COVID incidence may be lower with Omicron variants.²⁰

Still, those numbers are not trivial. Even at the lower Omicron-era rate, roughly half of the patients in that study reported some form of lingering symptoms. Fatigue and cognitive difficulties remained the most common complaints. Given the enormous number of Omicron infections worldwide, even a reduced percentage translates to a large absolute number of people dealing with long COVID.

Who Is Still at Serious Risk?

Immunocompromised individuals remain the most vulnerable group. People with weakened immune systems, including organ transplant recipients, those undergoing cancer treatment, and people on immunosuppressive medications, face elevated risks of severe outcomes even with Omicron. Some research has found that the gap in risk was greatest during earlier variant waves and somewhat narrowed during Omicron, but the risk for transplant recipients and others with suppressed immunity is still substantially higher than for the general population.²¹

Children generally handle COVID well, but the pattern of illness differs by variant. During Omicron waves, fever was the most common symptom in hospitalized children, and gastrointestinal symptoms became more prominent.²² Gastrointestinal symptoms in children with severe COVID have been associated with a higher likelihood of cardiac complications, which is worth keeping in mind for parents and pediatricians.²³ The combination of prior vaccination and past infection provides over 90% protection against severe COVID in the general population,²⁴ but young children and immunocompromised individuals of any age may not build up this layered immunity as effectively.

Do Rapid Tests Still Detect New Variants?

Most rapid antigen tests still work, but not all perform equally well across every variant. A comprehensive evaluation of 34 commercially available rapid tests against five different variants of concern found that several tests showed reduced sensitivity with certain variants, underscoring the need for ongoing performance checks as the virus evolves.²⁵ At least one newer combination test (detecting both COVID and influenza) demonstrated strong accuracy against Omicron specifically, with sensitivity around 95% and perfect specificity.²⁶

The practical takeaway: if you have symptoms and a home test says positive, trust it. If it says negative but you still feel sick, test again in a day or two. Rapid tests are generally better at detecting the virus when you have a higher viral load, which usually corresponds with peak contagiousness.

When COVID Meets Flu or RSV

With COVID settling into a seasonal rhythm alongside influenza and RSV, co-infections are getting more attention. Among adults visiting emergency departments, those with co-infections (COVID plus flu or RSV) had higher odds of being admitted to the hospital compared to those with just one virus. Severe outcomes were most frequent among people with RSV alone and those with co-infections.²⁷

In children, the picture is slightly different. A large study of hospitalized kids found that respiratory viral co-infection did not increase the odds of severe COVID overall, though children co-infected with RSV were about eight times more likely to need some form of breathing support.²⁸ Animal studies suggest the outcome of co-infection depends heavily on which virus arrives first and how much time passes between exposures.²⁹ In practical terms, getting vaccinated against all three viruses before the winter season reduces the chance of this kind of combined hit.

Tracking What Comes Next Through Sewage

One of the unsung tools in pandemic surveillance is wastewater monitoring. Sewage sampling has consistently detected new variants days to weeks before they appear in clinical testing. In Utah, wastewater sequencing picked up Omicron up to 10 days before the first clinical case was identified.³⁰ More recently, wastewater monitoring in India detected the JN.1 lineage a week before clinical samples did, and a subsequent subvariant three weeks ahead of clinical detection.³¹

This matters because as clinical testing rates have dropped, wastewater has become one of the best real-time indicators of which variants are circulating and whether a new wave is building. Many public health departments now publish wastewater data dashboards, and checking your region’s levels can give you a heads-up about local COVID activity before case counts catch up.

Animal Reservoirs and the Wildcard Factor

SARS-CoV-2 does not circulate only in humans. Several animal species, including mink, cats, dogs, and tigers, have been identified as susceptible hosts that could serve as amplification reservoirs.³² The concern is not just about animals getting sick. When the virus jumps into an animal population, replicates and mutates there, and then spills back into humans, it can acquire unexpected combinations of mutations that would not have arisen from human-to-human transmission alone. This is one of the mechanisms that researchers believe may have contributed to the sudden emergence of Omicron, which arrived with an unusually large number of mutations all at once.

Monitoring animal populations, particularly farmed animals like mink that live in dense conditions, remains an important part of the broader surveillance picture. Independent lineages circulating in Brazilian bat or rodent populations, for example, have shown their own convergent mutations in the spike protein’s key regions, mirroring what is happening in the human viral population.³³ The virus is finding similar evolutionary solutions in multiple hosts, which complicates long-term predictions about what will emerge next.

Making Sense of Risk Perception

How dangerous a variant “feels” and how dangerous it actually is are two different things, and both matter. Research on pandemic risk communication has found that public perception of danger is shaped not just by the actual threat but by contextual factors, including how information is framed, what is circulating on social media, and whether the threat feels novel or familiar.³⁴ Perception of risk, in turn, drives whether people take protective actions like getting vaccinated or wearing masks during surges.

At this stage of the pandemic, many people have swung toward dismissing COVID risk entirely, while others remain highly anxious about each new variant announcement. The evidence supports a middle ground: newer variants are genuinely less dangerous for most vaccinated, previously infected adults than what came before, but they are not trivial. They still kill tens of thousands of people annually, they still cause long-term symptoms in a meaningful minority of those infected, and they still pose serious threats to immunocompromised individuals. The most effective way to calibrate your personal risk is to consider your own immune status, whether you are up to date on vaccinations, and what local wastewater and hospitalization data indicate about current viral activity in your area.